KALV Profile
KalVista Pharmaceuticals Inc (KALV) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for the treatment of diseases with significant unmet medical need. The company's lead product candidate, KVD900, is an oral plasma kallikrein inhibitor that is being developed for the treatment of hereditary angioedema (HAE).
Here are some key highlights of KalVista Pharmaceuticals Inc:
The company's mission is to develop innovative therapies that address significant unmet medical needs in areas of high clinical importance, such as HAE, diabetic macular edema (DME), and other inflammatory diseases.
KVD900 is a plasma kallikrein inhibitor that is being evaluated in clinical trials for the treatment of HAE, a rare genetic disorder that causes episodes of swelling in various parts of the body.
The company has a deep pipeline of other potential protease inhibitors for the treatment of various diseases, including KVD001 for the treatment of DME and KVD824 for the treatment of various inflammatory diseases.
KalVista Pharmaceuticals Inc has partnerships with leading research institutions and pharmaceutical companies, which allows it to leverage their expertise and accelerate the development of its products.
The company is committed to responsible corporate citizenship and has a focus on sustainability and environmental, social, and governance (ESG) factors.
As of February 18, 2023, KalVista Pharmaceuticals Inc was listed on the NASDAQ stock exchange under the symbol KALV, with a market capitalization of approximately $580 million. The company's focus on innovative therapies for the treatment of diseases with significant unmet medical need may make it an attractive investment opportunity for investors looking to support companies that are making a difference in the field of healthcare.
|
